Biotage AB changes in number of shares and votes

As previously announced, the shareholders resolved at the Annual General Meeting
held on 26 April 2012 to withdraw 6,381,983 shares, which had been repurchased
under the company’s re-purchase program. Following withdrawal of these shares
the number of outstanding shares and votes amounts to 73,255,705 as of 31 May
2012.


Contact:
Torben Jörgensen, President and CEO
Tel: +46 707 49 05 84, torben.jorgensen@biotage.com


Biotage discloses the information provided herein pursuant to the Swedish
Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The
information was submitted for publication at 9.00 on 5 June 2012.


About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical
chemistry and medicinal chemistry. The customers include the world’s largest
pharmaceutical and biotech companies, and leading academic institutes. The
company is headquartered in Uppsala and has offices in the US, UK, China and
Japan. Biotage has 270 employees and had sales of 428.4 MSEK in 2011. Biotage is
listed on the NASDAQ OMX Nordic Stockholm stock exchange. Website:
www.biotage.com